

For Immediate Public Release:

RJH Biosciences ‘admitted’ to Berkeley Skydeck Fall’20 Cohort

- **RJH Biosciences selected from over 1800 applicant companies around the World**

EDMONTON, ALBERTA — November 4, 2020 — Today, RJH Biosciences Inc. has announced the decision by the Berkeley Skydeck to admit RJH Biosciences into the Fall 2020 Cohort of Berkeley SkyDeck. More than 1800 companies applied for selection to Fall 2020 Cohort and only 16 companies were selected. RJH Biosciences is pleased to be among this select group of companies. The Cohort companies receive a \$100,000 investment from the Berkeley SkyDeck Fund and access to 300 top advisors and mentors. RJH Biosciences Inc., a privately held biotech company in Edmonton, Alberta, was recognized for its novel technology that packages nucleic acids into virus-like particles and enables delivery of nucleic acids to specific types of cells.

Berkeley SkyDeck (skydeck.berkeley.edu) is UC Berkeley's global startup accelerator. Named by Forbes as one of the top five university accelerators, SkyDeck combines hands-on mentorship with the vast resources of its research university. SkyDeck is the only accelerator that provides funding for its startups via a public-private partnership, providing returns directly back to UC Berkeley from the Berkeley SkyDeck Fund, a dedicated investment fund supported by top institutional VCs like Sequoia and Mayfield. Participating startups have access to SkyDeck's 300 advisors, 50 industry partners, and a network of more than 510,000 UC Berkeley alumni. To date, SkyDeck startups have raised more than \$1.2 billion in aggregate. More information about the Fall 2020 cohort can be found at <https://finance.yahoo.com/news/16-startups-selected-uc-berkeley-150000585.html>.

RJH Biosciences is developing a series of non-viral transfection reagents that can be used for R&D and clinical testing. Based on a wealth of scientific and technological information generated in the last decade, tailored reagents to make nucleic acids functional in numerous systems have been commercialized. “We are delighted by Berkeley SkyDeck that recognized the potential of our technology and have seen its promise in the years to come. We are confident that our technology will be widely applied to better treat various diseases and leave no unturned stones in seeking cures to deadly diseases”, said Dr. Hasan Uludag, a biomedical engineer and the President of RJH Biosciences. The admission to SkyDeck is intended to develop the business case for spin-off companies from various institutions and provide tools to fully utilize the potential of the startup technologies.

About RJH Biosciences Inc.

RJH Biosciences Inc. is a University of Alberta spin-off company focusing on development of transfection reagents and delivery agents for nucleic acids. The goal of the company is to create effective therapies using nucleic acids to realize the dream of gene medicine. The company distributes its products via its website and undertakes projects on new medical treatments. More information about the company can be found at www.rjhbiosciences.com. The company has been funded in the past by Alberta Innovates, NRC-IRAP and Bill & Melinda Gates Foundation.

This public release contains forward-looking statements about potential future achievements and deliverables. The achievement or deliverables covered by such forward-looking statements involves risks, uncertainties and assumptions. These risks and uncertainties include, among other things, the company's ability to achieve certain technical milestones, to secure resources, including financial, to continue operations and the company's ability to realize benefits from strategic partnerships. If any such risks or uncertainties materialize or if any of the assumptions prove incorrect, the company's results could differ materially from the results expressed or implied by the forward-looking statements here. More information about this press release could be obtained by contacting RJH Biosciences Inc. at rjhbiosciences@gmail.com.